Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T16:37:38.842Z.
Calculation as of: 2026-10-06T16:37:38.842Z.
Quote observation: 2026-10-06T16:34:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f3696a2d024229c19dd1691f2f438020e28c75ff27c8cf4c9d796e14bd4a3b5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$24.74M
PS Ratio
N/A
TTM Avg
587.77
3Y Avg
330.78
5Y Avg
314.70
Market Cap
$27.70M
PS Ratio
14.71
TTM Avg
171.01
3Y Avg
556.63
5Y Avg
316.69
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iTonic Holdings Ltd. (ITOC) | $25.57M | N/A | N/A | N/A | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.74M | N/A | 587.77 | 330.78 | 314.70 |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.44M | N/A | 8459.04 | 2873.24 | 1783.28 |
| Kyntra Bio, Inc. (KYNB)vs › | $24.38M | 5.28 | 4.70 | 1.77 | 4.39 |
| InspireMD, Inc. (NSPR)vs › | $27.18M | 2.51 | 11.41 | 14.39 | 10.52 |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.70M | 14.71 | 171.01 | 556.63 | 316.69 |
| Rein Therapeutics Inc. (RNTX)vs › | $22.95M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.50M | 150.02 | 343.41 | 528.34 | 528.34 |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.31M | 0.39 | 0.46 | 0.28 | 0.24 |
| LeonaBio, Inc. (LONA)vs › | $22.24M | N/A | N/A | N/A | N/A |
Half-year reporter: no trailing two-half-year basis, because the half-year figures cannot be checked against the annual report: the newest completed fiscal year's annual revenue and net income are both below 25 million, too small to compare.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
